Skin Disorder
Why in News?
On 12 October 2026, the Yale School of Medicine announced it will co-lead the new Consortium for Hereditary Epidermal Differentiation Disorders (CHEDD) alongside Northwestern University to advance research on rare, inherited skin diseases.
What is the disorder group?
- The focus is hereditary epidermal differentiation disorders, an umbrella term recently adopted through international consensus classification.
- These are rare, inherited genetic skin diseases, formerly called ichthyoses and palmoplantar keratodermas.
- They arise from gene variants affecting skin structural proteins, lipid-metabolism enzymes and transporters, ion channels, and other components needed for a healthy skin barrier.
- Common visible features include skin thickening, scaling, and redness.
- Because the skin barrier is impaired, patients may face discomfort, infections, dehydration, and major quality-of-life challenges; the consortium aims to address the underlying biology rather than only symptoms.
About CHEDD
- Full name: Consortium for Hereditary Epidermal Differentiation Disorders.
- Announcement date: 12 October 2026.
- Co-leads: Yale School of Medicine and Northwestern University Feinberg School of Medicine.
- Yale lead: Dr. Keith A. Choate, chair of Dermatology at Yale.
- Northwestern lead: Dr. Amy S. Paller, chair of Dermatology at Northwestern.
- Participants: Seven clinical sites, patient advocacy organisations, and the RDCRN Data Management and Coordinating Center.
- Other clinical sites: Stanford University; UC San Diego and Rady Children’s Hospital; University of Colorado; Medical University of South Carolina; and University of Texas at Austin with Dell Children’s Medical Center.
Three research projects
| Project | Main aim |
|---|---|
| Project 1 | Create a long-term patient registry and natural-history study, linking genetic diagnosis with standardised clinical assessments to understand disease progression and identify trial outcome measures. |
| Project 2 | Conduct a clinical trial of erlotinib, an oral targeted drug, to test whether blocking an overactive skin growth-signalling pathway improves disease. |
| Project 3 | Map molecular changes behind different subtypes and identify biomarkers for disease activity and treatment response. |
Significance
- It enables multi-centre research at a scale no single hospital could achieve.
- It combines genetic diagnosis, long-term follow-up, molecular analysis, and clinical trials.
- It may help match patients to therapies that target the root genetic or molecular cause, rather than offering only general skin care.
- It could create validated outcome measures and biomarkers needed for future treatments and clinical trials.
